Yazar "Kowdley, Kris V." için listeleme
-
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, Mary E.; Lazarus, Jeffrey V.; Ratziu, Vlad; Francque, Sven M.; Sanyal, Arun J.; Kanwal, Fasiha; Romero, Diana; Abdelmalek, Manal F.; Anstee, Quentin M.; Arab, Juan Pablo; Arrese, Marco; Bataller, Ramon; Beuers, Ulrich; Boursier, Jerome; Bugianesi, Elisabetta; Byrne, Christopher D.; Castro Narro, Graciela E.; Chowdhury, Abhijit; Cortez-Pinto, Helena; Cryer, Donna R.; Cusi, Kenneth; El-Kassas, Mohamed; Klein, Samuel; Eskridge, Wayne; Fan, Jiangao; Gawrieh, Samer; Guy, Cynthia D.; Harrison, Stephen A.; Kim, Seung Up; Koot, Bart G.; Korenjak, Marko; Kowdley, Kris V.; Lacaille, Florence; Loomba, Rohit; Mitchell-Thain, Robert; Morgan, Timothy R.; Powell, Elisabeth E.; Roden, Michael; Romero-Gómez, Manuel; Silva, Marcelo; Singh, Shivaram Prasad; Sookoian, Silvia C.; Spearman, C. Wendy; Tiniakos, Dina; Valenti, Luca; Vos, Miriam B.; Wong, Vincent Wai-Sun; Xanthakos, Stavra; Yılmaz, Yusuf; Younossi, Zobair; Hobbs, Ansley; Villota-Rivas, Marcela; Newsome, Philip N. (Elsevier, 2023)The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient ... -
A phase 3 trial of seladelpar in primary biliary cholangitis
Hirschfield, Gideon M.; Bowlus, Christopher L.; Mayo, Marlyn J.; Kremer, Andreas E.; Vierling, John M.; Kowdley, Kris V.; Levy, Cynthia; Villamil, Alejandra; Ladrón de Guevara Cetina, Alma L.; Janczewska, Ewa; Zigmond, Ehud; Jeong, Sook-Hyang; Yılmaz, Yusuf; Kallis, Yiannis; Corpechot, Christophe; Buggisch, Peter; Invernizzi, Pietro; Hurtado, Maria Carlota Londoño; Bergheanu, Sandrin; Yang, Ke; Choi, Yun-Jung; Crittenden, Daria B.; McWherter, Charles A. (Massachussetts Medical Society, 2024)Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS In this phase 3, 12-month, double-blind, ...
